New flow cytometric assays for monitoring cell-mediated cytotoxicity.
The exact immunologic responses after vaccination that result in effective antitumor immunity have not yet been fully elucidated and the data from ex vivo T-cell assays have not yet defined adequate surrogate markers for clinical efficacy. A more detailed knowledge of the specific immune responses that correlate with positive clinical outcomes should help to develop better or novel strategies to effectively activate the immune system against tumors. Furthermore, clinically relevant material is often limited and, thus, precludes the ability to perform multiple assays. The two main assays currently used to monitor lymphocyte-mediated cytoxicity in cancer patients are the (51)Cr-release assay and IFN-gamma ELISpot assay. The former has a number of disadvantages, including low sensitivity, poor labeling and high spontaneous release of isotope from some tumor target cells. Additional problems with the (51)Cr-release assay include difficulty in obtaining autologous tumor targets, and biohazard and disposal problems for the isotope. The ELISpot assays do not directly measure cytotoxic activity and are, therefore, a surrogate marker of cyotoxic capacity of effector T cells. Furthermore, they do not assess cytotoxicity mediated by the production of the TNF family of death ligands by the cytotoxic cells. Therefore, assays that allow for the simultaneous measurement of several parameters may be more advantageous for clinical monitoring. In this respect, multifactor flow cytometry-based assays are a valid addition to the currently available immunologic monitoring assays. Use of these assays will enable detection and enumeration of tumor-specific cytotoxic T lymphocytes and their specific effector functions and any correlations with clinical responses. Comprehensive, multifactor analysis of effector cell responses after vaccination may help to detect factors that determine the success or failure of a vaccine and its immunological potency.
Applied and Developmental Research Support Program, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD, USA.
Liubov
L
Zaritskaya
Michael R
MR
Shurin
Thomas J
TJ
Sayers
Anatoli M
AM
Malyguine
D000818:Animals; D017209:Apoptosis; D019496:Cancer Vaccines / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D005434:Flow Cytometry / Q000379:methods*; D006801:Humans; D052118:Lysosomal-Associated Membrane Protein 1 / Q000032:analysis; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014611:Vaccination
D019496:Cancer Vaccines; D052118:Lysosomal-Associated Membrane Protein 1